Tempest Announces Publication In Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models By Blocking EP2 And EP4 Together
Portfolio Pulse from Benzinga Newsdesk
Tempest Therapeutics has announced that its drug TPST-1495 has shown increased potency against prostaglandin-driven tumor models by blocking EP2 and EP4 receptors. The drug's anti-tumor response is both immune dependent and immune independent. These preclinical findings support the previously reported Phase 1 clinical results for TPST-1495, which showed tumor shrinkage and prolonged disease control in both monotherapy and in combination with pembrolizumab.
July 19, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tempest's TPST-1495 has shown promising results in preclinical trials, potentially boosting the company's prospects.
The positive preclinical results for TPST-1495 suggest that the drug could be effective in treating certain types of cancer. This could potentially lead to regulatory approval and commercial success, which would likely have a positive impact on Tempest's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100